All Articles
The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes. Read More ›
Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020. Read More ›
On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020. Read More ›
On January 23, 2020, the FDA granted accelerated approval to tazemetostat (Tazverik; Epizyme), a methyltransferase inhibitor, for the treatment of metastatic or locally advanced epithelioid sarcoma in adults and pediatric patients aged ≥16 years who are not eligible for complete resection. Read More ›
There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes will affect many patients’ out-of-pocket spending for anticancer drugs, including poly (ADP-ribose) polymerase inhibitors. Read More ›
A bipartisan bill designed to remove disparity in pricing between intravenously administered drugs and orally administered drugs for patients with cancer was passed in the House in March 2019 but awaits action in the Senate. Read More ›
CMS approves changes allowing limited utilization management in protected classes of drugs. However, other proposed changes that would have further eroded patient access were not implemented. Read More ›
The Final Rule by the HSS means that manufacturers’ copay cards or coupons do not apply to a patient’s deductible or out-of-pocket maximum limits in certain situations, but further clarification is needed. Read More ›
Results from 3 clinical trials demonstrate the value of PARP inhibitors as first-line or maintenance therapies in patients with advanced ovarian cancer. Read More ›
Learn how the Oncology Care First (OCF) model breaks down and what it means for community oncology from Tuple Health and Flatiron Health experts. Read More ›